<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004029</url>
  </required_header>
  <id_info>
    <org_study_id>17P-ES-003</org_study_id>
    <nct_id>NCT01004029</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery</brief_title>
  <acronym>PROLONG</acronym>
  <official_title>A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate (HPC) Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResearchPoint Global</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As part of the continuing effort to study the benefit and risks of 17P and preterm delivery,&#xD;
      this study is designed as a multi-center, randomized, double-blind, vehicle-controlled&#xD;
      clinical trial of 17P for the prevention of preterm birth prior to 35 weeks, 0 days of&#xD;
      gestation in women with a singleton pregnancy, aged 18 years or older, with a previous&#xD;
      singleton spontaneous preterm delivery. The study also includes a population pharmacokinetic&#xD;
      (PK) substudy to assess the hydroxyprogesterone caproate (HPC) exposure-response relationship&#xD;
      and the effect of body mass index (BMI) on the PK of 17P.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most significant risk factors for preterm birth is previous pregnancy history.&#xD;
      Women who have had a prior preterm birth have a 2.5-fold greater risk than women with no&#xD;
      prior history of preterm birth. Prophylactic methods for prevention of preterm birth,&#xD;
      including tocolytic drugs, bed rest, and other interventions such as cerclage, have been&#xD;
      shown in most studies to be ineffective. One of the preventive measures that has shown&#xD;
      effectiveness in randomized trials is the use of progesterone agents.9,10 Progesterone has&#xD;
      been shown to support gestation and to inhibit uterine activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2009</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm Birth &lt;35 Weeks Gestation</measure>
    <time_frame>Up to 35 weeks</time_frame>
    <description>Determine if treatment with 17P reduces the rate of preterm birth &lt; 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal Composite Index (NCI)</measure>
    <time_frame>Until 28 days of life or discharge from the neonatal intensive care unit (NICU), whichever occurred later.</time_frame>
    <description>The composite index is defined as a liveborn neonate with any of the following occurring at any time during the birth hospitalization up through discharge from the NICU: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or proven sepsis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal/Early Infant Death</measure>
    <time_frame>Delivery from 16 weeks 0 days through 19 weeks 6 days of gestation; or neonatal death occurring in liveborns born at less than 24 weeks gestation; or stillbirth (antepartum or intrapartum death) from 20 weeks gestation through term).</time_frame>
    <description>Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth Prior to 32 Weeks Gestation</measure>
    <time_frame>Up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth Prior to 37 Weeks Gestation</measure>
    <time_frame>Up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirths</measure>
    <time_frame>20 weeks gestation until term</time_frame>
    <description>Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Deaths With ≥24 Weeks Gestational Age</measure>
    <time_frame>Until 28 days of life or discharge from the NICU whichever occurred later.</time_frame>
    <description>Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1740</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Castor Oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HPC 250 mg/mL in oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL</intervention_name>
    <description>1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
    <arm_group_label>Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL</arm_group_label>
    <other_name>Makena</other_name>
    <other_name>17P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet the following criteria to be enrolled in this study:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Singleton gestation.&#xD;
&#xD;
          3. Project gestational age 16 weeks 0 days of gestation or more and less than or equal to&#xD;
             20 weeks 6 days of gestation at the time of randomization, based on clinical&#xD;
             information and evaluation of the first ultrasound.&#xD;
&#xD;
          4. Documented history of a previous singleton spontaneous preterm delivery. Spontaneous&#xD;
             preterm birth is defined as delivery from 20 weeks 0 days to 36 weeks 6 days of&#xD;
             gestation following spontaneous preterm labor or pPROM. Where possible, the&#xD;
             gestational age of the previous preterm birth (referred to as the qualifying delivery)&#xD;
             should be determined as described in &quot;Gestational Age Determination&quot;. If the&#xD;
             gestational age at delivery is obtained directly from the medical record and more than&#xD;
             one gestational age appears, the latest will be used. As a validation of the&#xD;
             gestational age of the previous delivery, if the infant weighed more than 3300 grams&#xD;
             (the birth weight 90th percentile for 36 weeks gestational age), this will not qualify&#xD;
             as preterm. The previous preterm delivery cannot be an antepartum stillbirth.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multifetal gestation.&#xD;
&#xD;
          2. Known major fetal anomaly or fetal demise. An ultrasound examination between 14 weeks&#xD;
             0 days through 20 weeks 3 days of gestation must be performed to rule out fetal&#xD;
             anomalies.&#xD;
&#xD;
          3. Progesterone treatment in any form (i.e., vaginal, oral, intramuscular) during current&#xD;
             pregnancy, other than micronized progesterone delivered orally or vaginally provided&#xD;
             it is stopped at least 4 weeks prior to the first dose of study medication.&#xD;
&#xD;
          4. Heparin therapy during current pregnancy or history of thromboembolic disease.&#xD;
&#xD;
          5. Maternal medical/obstetrical complications including:&#xD;
&#xD;
               -  Current or planned cerclage&#xD;
&#xD;
               -  Hypertension requiring medication&#xD;
&#xD;
               -  Seizure disorder&#xD;
&#xD;
          6. Subjects with a uterine anomaly (uterine didelphys or bicornate uterus). However,&#xD;
             subjects with uterine fibroids are eligible for the study.&#xD;
&#xD;
          7. Unwillingness to comply with and complete the study.&#xD;
&#xD;
          8. A 14 weeks 0 days through 20 weeks 3 days of gestation ultrasound cannot be arranged&#xD;
             before randomization.&#xD;
&#xD;
          9. Participation in an antenatal study in which the clinical status or intervention may&#xD;
             influence gestational age at delivery.&#xD;
&#xD;
         10. Participation in this trial in a previous pregnancy. Women who were screened in a&#xD;
             previous pregnancy, but not randomized, do not have to be excluded.&#xD;
&#xD;
         11. Known hypersensitivity to hydroxyprogesterone caproate or its components.&#xD;
&#xD;
         12. Have any significant medical disorder that, in the opinion of the investigator, would&#xD;
             be a contraindication to the use of the drug including those listed in section 5.3.2&#xD;
             of the investigational brochure. Other examples to consider include uncontrolled&#xD;
             diabetes, known HIV infection or renal dysfunction.&#xD;
&#xD;
         13. Have any significant medical disorder that, in the opinion of the investigator, would&#xD;
             preclude accurate evaluation of the subject's condition or outcome in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Drug Research &amp; Analysis Corporation</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Medical Center (Watching Over Mothers and Babies Foundation)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grossmont Center for Clinical Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego - Department of Obstetrics and Gynecology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Health Specialists</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Associates, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Rocks OB/GYN - Physician's Research Options, LLC</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Obstetrics &amp; Gynecology, PA (Altus Research)</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global OB/GYN Centers</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Millennium Obstetrics &amp; Gynecology, LLc</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Clinic</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosemark Women Care Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Care Physicians/Obstetrical Specialists, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Z. Lenowitz, MD, LLC</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Female Pelvic Medicine and Urogynecology Institute of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group, LLC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womack Army Medical Center</name>
      <address>
        <city>Fort Bragg</city>
        <state>North Carolina</state>
        <zip>28310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triad Research Partners, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Dakota clinicl, PC Center for Women</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HWC Women's Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Clinical Research Center, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Group</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Physician's Group, MPLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Research Organization, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl R. Darnall Army Medical Center</name>
      <address>
        <city>Fort Hood</city>
        <state>Texas</state>
        <zip>76544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates Rio Grande Valley</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Timpanogos Women's Health Care</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Women's Center, P.C.</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheaton Franciscan Healthcare - St. Joseph Campus</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Blagoevgrad&quot;, Department of obstetrics and Gynecology</name>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center &quot;Teodora&quot;, LTD</name>
      <address>
        <city>Russe</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Silistra&quot;, Obstetrics and Gynecology Department</name>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Medical institute of Interior ministry&quot;, Sofia city PLC, Department of Gynecology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre &quot;Avicena&quot; Ltd</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT &quot; Sheinovo &quot;,PLS, Maternity Clinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Foothills Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>AB T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lion's Gate Hospital (University of BC)</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7M 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glazier Medical Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victory Reproductive Care</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Leung Obstetrics and Gynaecology</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravsky KRAJ</state>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucky KRAJ</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice, a.s. Gynekologicko-pordnicka klinika</name>
      <address>
        <city>Ceske Budejovice 7</city>
        <zip>37001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove Porodnicka a gynekologicka klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava Porodnicko-gynekologicka klinika</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Pizen Gynekologicko-pordnicka klinika</name>
      <address>
        <city>Plzen-Lochotin</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum, Szuleszeti es Nogyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Szuleszet - Nogyogyaszat</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz, Szuleszet-Nogyogyaszat</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Onkormanyzat Korhaza, Svegedi Tudmanyegyetem Altalanos Orvostudomanyi kar Oktato Korhaza</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktato Korhaz Egeszsegugyi Szolgaltato Nonprofit Kft.</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem, Szuleszeti es Nogyogyaszati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Bolzano Ospedale Generale Regionale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia - Ospedale Santa Maria dell a Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern State Medical University</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern State Medical University</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgorod Regional Clinical Hospital of St.Ioasaf</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Kazan State Medical University of RosZdrav&quot;</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo State Medical Academy</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Krasnoyarsk State University named After Prof. V.F. Voino-Yasenetsky of Ministry of Health Russia&quot; Department of Perinatology, Obstetrics and Gynecology of Medical Faculty</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;People's Friendship University of Russia&quot; Department of Obstetrics and Gynecology with Course Perinatology</name>
      <address>
        <city>Moscow</city>
        <zip>117333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University named after N.I. Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;Novosibirsk Municipal Perinatal Centre&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Medical State University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov Federal Heart, Blood and Endocrinology Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;St. Petersburg l.l Mechnikov State Medical Academy of RosZdrav&quot; Department of Obstetrics, Gynecology and Perinatology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;D.O. Otto Scientific Institute for Obstetrics and Gynecology&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Perinatal Center</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Regional Maternity Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Ural Research Institute of Maternity and Infancy Care of Rosmedtechnologies&quot;</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Materno Infantil de Canarias</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Maternity Hospital #1</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donets'k Regional Centre of Mother and Child Care</name>
      <address>
        <city>Donets'k</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivs'k Regional Prenatal Center, department of pregnant pathology</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&lt;&lt;Institute of Pediatrics, Obstetrics and Gynecology of AMS Ukraine&gt;&gt; Department of Rehabilitation and Reproduktive function of Women</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic #1, Obolon district of Kyiv, maternity welfare department</name>
      <address>
        <city>Kyiv</city>
        <zip>04220</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Centre of Reproduction and perinatal medicine, obstetric department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Institute of pediatrics, obstetrics and gynecology of AMS of Ukraine&quot;. Department of extragenital pathology and postnatal rehabilitation</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Maternity Hospital #1&quot;</name>
      <address>
        <city>Odessa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil' Municipal Hospital # 2</name>
      <address>
        <city>Ternopil</city>
        <zip>46001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod Municipal prenatal Centre, maternity welfare department #2</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Maternity Hospital No 4</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology of Zhaporizhzhya Medical Academy of Postgraduate Education on the Base of Healthcare Institution Maternity Hospital No 3</name>
      <address>
        <city>Zhaporizhzhya</city>
        <zip>69071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>17P</keyword>
  <keyword>17-HPC</keyword>
  <keyword>17-OHPC</keyword>
  <keyword>17-hydroxyprogesterone caproate</keyword>
  <keyword>progestogens</keyword>
  <keyword>preterm birth</keyword>
  <keyword>recurrent preterm birth</keyword>
  <keyword>spontaneous preterm birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01004029/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01004029/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1740 subjects enrolled (signed the informed consent form), but only 1708 were randomized to each group (10 subjects did not return for Visit 2, 8 subjects did not meet all eligibility requirements, 8 subjects withdrew consent, and 6 subjects discontinued for other reasons).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle</title>
          <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="P2">
          <title>17P (Hydroxyprogesterone Caproate Injection)</title>
          <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="578"/>
                <participants group_id="P2" count="1130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="578"/>
                <participants group_id="P2" count="1128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="530"/>
                <participants group_id="P2" count="1057"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle</title>
          <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="B2">
          <title>17P (Hydroxyprogesterone Caproate Injection)</title>
          <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="578"/>
            <count group_id="B2" value="1130"/>
            <count group_id="B3" value="1708"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="578"/>
                    <count group_id="B2" value="1130"/>
                    <count group_id="B3" value="1708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="5.22"/>
                    <measurement group_id="B2" value="30" spread="5.17"/>
                    <measurement group_id="B3" value="30.0" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="578"/>
                    <count group_id="B2" value="1130"/>
                    <count group_id="B3" value="1708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="578"/>
                    <measurement group_id="B2" value="1130"/>
                    <measurement group_id="B3" value="1708"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="578"/>
                    <count group_id="B2" value="1130"/>
                    <count group_id="B3" value="1708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="524"/>
                    <measurement group_id="B2" value="1029"/>
                    <measurement group_id="B3" value="1553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="578"/>
                    <count group_id="B2" value="1130"/>
                    <count group_id="B3" value="1708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="1004"/>
                    <measurement group_id="B3" value="1508"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-pregnancy BMI (kg/m2), n</title>
          <population>One participant did not have height recorded therefore BMI could not be calculated.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="577"/>
                    <count group_id="B2" value="1130"/>
                    <count group_id="B3" value="1707"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="8.65"/>
                    <measurement group_id="B2" value="24.3" spread="7.05"/>
                    <measurement group_id="B3" value="24.5" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preterm Birth &lt;35 Weeks Gestation</title>
        <description>Determine if treatment with 17P reduces the rate of preterm birth &lt; 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery.</description>
        <time_frame>Up to 35 weeks</time_frame>
        <population>Number of ITT (intent to treat) subjects with non-missing delivery data or who were known to still be pregnant at 35 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth &lt;35 Weeks Gestation</title>
          <description>Determine if treatment with 17P reduces the rate of preterm birth &lt; 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery.</description>
          <population>Number of ITT (intent to treat) subjects with non-missing delivery data or who were known to still be pregnant at 35 weeks</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="574"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neonatal Composite Index (NCI)</title>
        <description>The composite index is defined as a liveborn neonate with any of the following occurring at any time during the birth hospitalization up through discharge from the NICU: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or proven sepsis.</description>
        <time_frame>Until 28 days of life or discharge from the neonatal intensive care unit (NICU), whichever occurred later.</time_frame>
        <population>Liveborn Neonatal Population</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Composite Index (NCI)</title>
          <description>The composite index is defined as a liveborn neonate with any of the following occurring at any time during the birth hospitalization up through discharge from the NICU: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or proven sepsis.</description>
          <population>Liveborn Neonatal Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="559"/>
                <count group_id="O2" value="1093"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal/Early Infant Death</title>
        <description>Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group</description>
        <time_frame>Delivery from 16 weeks 0 days through 19 weeks 6 days of gestation; or neonatal death occurring in liveborns born at less than 24 weeks gestation; or stillbirth (antepartum or intrapartum death) from 20 weeks gestation through term).</time_frame>
        <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal/Early Infant Death</title>
          <description>Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group</description>
          <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="578"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Birth Prior to 32 Weeks Gestation</title>
        <time_frame>Up to 32 weeks</time_frame>
        <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth Prior to 32 Weeks Gestation</title>
          <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="578"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Birth Prior to 37 Weeks Gestation</title>
        <time_frame>Up to 37 weeks</time_frame>
        <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth Prior to 37 Weeks Gestation</title>
          <population>Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="578"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stillbirths</title>
        <description>Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term.</description>
        <time_frame>20 weeks gestation until term</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxyprogesterone Caproate Injection, 250 mg/mL</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Stillbirths</title>
          <description>Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="559"/>
                <count group_id="O2" value="1093"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Deaths With ≥24 Weeks Gestational Age</title>
        <description>Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater</description>
        <time_frame>Until 28 days of life or discharge from the NICU whichever occurred later.</time_frame>
        <population>Liveborn Neonatal Population - all babies of randomized women who were liveborn and have morbidity data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>17P (Hydroxyprogesterone Caproate Injection)</title>
            <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Deaths With ≥24 Weeks Gestational Age</title>
          <description>Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater</description>
          <population>Liveborn Neonatal Population - all babies of randomized women who were liveborn and have morbidity data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="1093"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomized subjects were followed up to 35 ± 7 days after the last dose of study drug. Maternal and fetal deaths were reported until delivery if delivery occurred after 35 ± 7 days after last dose.</time_frame>
      <desc>Subjects reporting a particular adverse event (preferred term) or maternal pregnancy complication more than once are counted only once by preferred term and System Organ Class.&#xD;
All cause mortality used the ITT population. Serious and Other Adverse events used the Safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Castor Oil&#xD;
Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="E2">
          <title>17P (Hydroxyprogesterone Caproate Injection)</title>
          <description>HPC 250 mg/mL in oil&#xD;
Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Cholestasis of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Choriaoamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Mastitis postpartum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Pelvic abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>bladder injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy chorionic villous abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Central nervous system inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Placental insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="647" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Afterbirth pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Placental disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1128"/>
              </event>
              <event>
                <sub_title>Preeclampsia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Shortened cervix</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="578"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>AMAG Pharmaceuticals</organization>
      <phone>1-877-411-2510</phone>
      <email>amag@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

